{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T18:57:30Z","timestamp":1791917850757,"version":"4.3.4"},"reference-count":84,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2024,12,17]],"date-time":"2024-12-17T00:00:00Z","timestamp":1734393600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,28]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>The treatment landscape for immunoglobulin A nephropathy is rapidly evolving with the introduction of novel therapies targeting diverse disease pathways. Some have already been approved in different countries, while others are under investigation in randomized controlled trials (RCTs) with encouraging results. However, almost all performed RCTs have included only patients with refractory non-nephrotic proteinuria and preserved renal function. Other clinical presentations (rapidly progressive forms, malignant hypertension, thrombotic microangiopathy, nephrotic syndrome) have received less attention and are systematically excluded from RCTs. In contrast, certain aspects, such as the impact of haematuria or management in special populations (e.g. pregnant patients or transplant recipients), remain underexplored. This review proposes therapeutic algorithms to guide treatment decisions in different clinical scenarios while highlighting gaps in current research.<\/jats:p>","DOI":"10.1093\/ndt\/gfae289","type":"journal-article","created":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T23:40:03Z","timestamp":1733960403000},"page":"874-883","source":"Crossref","is-referenced-by-count":15,"title":["Tailored management strategies for IgA nephropathy based on clinical presentations"],"prefix":"10.1093","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9270-1071","authenticated-orcid":false,"given":"Manuel","family":"Praga","sequence":"first","affiliation":[{"name":"Universidad Complutense de Madrid Department of Medicine, , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5830-9663","authenticated-orcid":false,"given":"Fernando","family":"Caravaca-Font\u00e1n","sequence":"additional","affiliation":[{"name":"Instituto de Investigaci\u00f3n Hospital 12 de Octubre Department of Nephrology, , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iara","family":"Da Silva","sequence":"additional","affiliation":[{"name":"Hospital Universitario Germans Trias i Pujol Department of Nephrology, , Badalona, Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gema","family":"Fern\u00e1ndez-Ju\u00e1rez","sequence":"additional","affiliation":[{"name":"Hospital Universitario La Paz Department of Nephrology, , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Guti\u00e9rrez","sequence":"additional","affiliation":[{"name":"Hospital Universitario 12 de Octubre Department of Nephrology, , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angel M","family":"Sevillano","sequence":"additional","affiliation":[{"name":"Hospital Universitario 12 de Octubre Department of Nephrology, , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hernan","family":"Trimarchi","sequence":"additional","affiliation":[{"name":"Hospital Brit\u00e1nico de Buenos Aires Department of Nephrology, , Buenos Aires ,","place":["Argentina"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,12,17]]},"reference":[{"key":"2025042804361094200_bib1","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1007\/s00281-021-00888-3","article-title":"Current treatment of IgA nephropathy","volume":"43","author":"Floege","year":"2021","journal-title":"Semin Immunopathol"},{"key":"2025042804361094200_bib2","doi-asserted-by":"publisher","first-page":"2515","DOI":"10.1016\/j.ekir.2023.09.020","article-title":"Evaluating progression risk in patients with immunoglobulin A nephropathy","volume":"8","author":"Cattran","year":"2023","journal-title":"Kidney Int Rep"},{"key":"2025042804361094200_bib3","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1681\/ASN.0000000000000242","article-title":"Treatment of IgA nephropathy: a rapidly evolving field","volume":"35","author":"El Karoui","year":"2024","journal-title":"J Am Soc Nephrol"},{"key":"2025042804361094200_bib4","doi-asserted-by":"publisher","first-page":"3177","DOI":"10.1681\/ASN.2007050526","article-title":"Remission of proteinuria improves prognosis in IgA nephropathy","volume":"18","author":"Reich","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"2025042804361094200_bib5","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1053\/j.ajkd.2021.03.007","article-title":"Association of treatment effects on early change in urine protein and treatment effects on GFR slope in IgA nephropathy: an individual participant meta-analysis","volume":"78","author":"Inker","year":"2021","journal-title":"Am J Kidney Dis"},{"key":"2025042804361094200_bib6","doi-asserted-by":"publisher","first-page":"727","DOI":"10.2215\/CJN.0000000000000135","article-title":"Long-term outcomes in IgA nephropathy","volume":"18","author":"Pitcher","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025042804361094200_bib7","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1038\/ki.2015.241","article-title":"Identifying the ideal metric of proteinuria as a predictor of renal outcome in idiopathic glomerulonephritis","volume":"88","author":"Barbour","year":"2015","journal-title":"Kidney Int"},{"key":"2025042804361094200_bib8","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1038\/ki.2014.63","article-title":"Validation of the Oxford classification of IgA nephropathy in cohorts with different presentations and treatments","volume":"86","author":"Coppo","year":"2014","journal-title":"Kidney Int"},{"key":"2025042804361094200_bib9","doi-asserted-by":"publisher","first-page":"3089","DOI":"10.1681\/ASN.2017010108","article-title":"Remission of hematuria improves renal survival in IgA nephropathy","volume":"28","author":"Sevillano","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"2025042804361094200_bib10","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1093\/ndt\/gfz267","article-title":"The association of microhematuria with mesangial hypercellularity, endocapillary hypercellularity, crescent score and renal outcomes in immunoglobulin A nephropathy","volume":"36","author":"Bobart","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"2025042804361094200_bib11","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1053\/j.ajkd.2019.11.008","article-title":"Persistent hematuria and kidney disease progression in IgA nephropathy: a cohort study","volume":"76","author":"Yu","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"2025042804361094200_bib12","doi-asserted-by":"publisher","first-page":"ii19","DOI":"10.1093\/ckj\/sfad232","article-title":"Microscopic hematuria as a risk factor for IgAN progression: considering this biomarker in selecting and monitoring patients","volume":"16","author":"Zand","year":"2023","journal-title":"Clin Kidney J"},{"key":"2025042804361094200_bib13","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/j.kint.2017.02.003","article-title":"Oxford classification of IgA nephropathy 2016: an update from the IgA Nephropathy Classification Working Group","volume":"91","author":"Trimarchi","year":"2017","journal-title":"Kidney Int"},{"key":"2025042804361094200_bib14","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1681\/ASN.2012010063","article-title":"Long-term outcomes of IgA nephropathy presenting with minimal or no proteinuria","volume":"23","author":"Guti\u00e9rrez","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"2025042804361094200_bib15","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1093\/ndt\/17.1.64","article-title":"Prognostic indicators of IgA nephropathy in the Chinese\u2014clinical and pathological perspectives","volume":"17","author":"Li","year":"2002","journal-title":"Nephrol Dial Transplant"},{"key":"2025042804361094200_bib16","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1056\/NEJMoa1415463","article-title":"Intensive supportive care plus immunosuppression in IgA nephropathy","volume":"373","author":"Rauen","year":"2015","journal-title":"N Engl J Med"},{"key":"2025042804361094200_bib17","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.kint.2021.05.015","article-title":"Executive summary of the KDIGO 2021 guideline for the management of glomerular diseases","volume":"100","author":"Rovin","year":"2021","journal-title":"Kidney Int"},{"key":"2025042804361094200_bib18","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1097\/01.ASN.0000068460.37369.DC","article-title":"Treatment of IgA nephropathy with ACE inhibitors","volume":"14","author":"Praga","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"2025042804361094200_bib19","doi-asserted-by":"publisher","first-page":"1880","DOI":"10.1681\/ASN.2006040347","article-title":"IgACE","volume":"18","author":"Coppo","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"2025042804361094200_bib20","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"EMPA-KIDNEY Collaborative Group","year":"2023","journal-title":"N Engl J Med"},{"key":"2025042804361094200_bib21","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"2025042804361094200_bib22","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1093\/ndt\/gfad175","article-title":"Sodium-glucose cotransporter 2 inhibition in primary and secondary glomerulonephritis","volume":"39","author":"Caravaca-Font\u00e1n","year":"2024","journal-title":"Nephrol Dial Transplant"},{"key":"2025042804361094200_bib23","doi-asserted-by":"publisher","first-page":"2198","DOI":"10.1016\/j.ekir.2023.07.023","article-title":"Targeting the endothelin A receptor in IgA nephropathy","volume":"8","author":"Kohan","year":"2023","journal-title":"Kidney Int Rep"},{"key":"2025042804361094200_bib24","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1016\/S0140-6736(23)00569-X","article-title":"Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial","volume":"401","author":"Heerspink","year":"2023","journal-title":"Lancet"},{"key":"2025042804361094200_bib25","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1016\/S0140-6736(23)02302-4","article-title":"Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial","volume":"402","author":"Rovin","year":"2023","journal-title":"Lancet"},{"key":"2025042804361094200_bib26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2409415","article-title":"Atrasentan in patients with IgA nephropathy","volume":"392","author":"Heerspink","year":"2025","journal-title":"N Engl J Med"},{"key":"2025042804361094200_bib27","doi-asserted-by":"publisher","first-page":"4973","DOI":"10.1097\/MS9.0000000000001180","article-title":"Efficacy and safety of finerenone in chronic kidney disease and type 2 diabetes patients: a systematic review and meta-analysis","volume":"85","author":"Yasmin","year":"2023","journal-title":"Ann Med Surg"},{"key":"2025042804361094200_bib28","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1159\/000517020","article-title":"The forgotten antiproteinuric properties of diuretics","volume":"52","author":"Trujillo","year":"2021","journal-title":"Am J Nephrol"},{"key":"2025042804361094200_bib29","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/S0140-6736(98)03563-6","article-title":"Corticosteroids in IgA nephropathy: a randomised controlled trial","volume":"353","author":"Pozzi","year":"1999","journal-title":"Lancet"},{"key":"2025042804361094200_bib30","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.1681\/ASN.2014070697","article-title":"Corticosteroids in IgA nephropathy","volume":"26","author":"Tesar","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"2025042804361094200_bib31","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1016\/j.kint.2020.04.046","article-title":"After ten years of follow-up, no difference between supportive care plus immunosuppression and supportive care alone in IgA nephropathy","volume":"98","author":"Rauen","year":"2020","journal-title":"Kidney Int"},{"key":"2025042804361094200_bib32","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1001\/jama.2017.9362","article-title":"Effect of oral methylprednisolone on clinical outcomes in patients with IgA nephropathy","volume":"318","author":"Lv","year":"2017","journal-title":"JAMA"},{"key":"2025042804361094200_bib33","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1001\/jama.2022.5368","article-title":"Effect of oral methylprednisolone on decline in kidney function or kidney failure in patients with IgA nephropathy","volume":"327","author":"Lv","year":"2022","journal-title":"JAMA"},{"key":"2025042804361094200_bib34","doi-asserted-by":"publisher","first-page":"2157","DOI":"10.1681\/ASN.2010020181","article-title":"The anti-fibrotic effect of mycophenolic acid-induced neutral endopeptidase","volume":"21","author":"Dell'Oglio","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"2025042804361094200_bib35","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1111\/j.1523-1755.2004.00588.x","article-title":"Mycophenolate mofetil in IgA nephropathy: results of a 3-year prospective placebo-controlled randomized study","volume":"65","author":"Maes","year":"2004","journal-title":"Kidney Int"},{"key":"2025042804361094200_bib36","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1053\/j.ajkd.2016.11.027","article-title":"Mycophenolate mofetil combined with prednisone versus full-dose prednisone in IgA nephropathy with active proliferative lesions: a randomized controlled trial","volume":"69","author":"Hou","year":"2017","journal-title":"Am J Kidney Dis"},{"key":"2025042804361094200_bib37","doi-asserted-by":"publisher","first-page":"e2254054","DOI":"10.1001\/jamanetworkopen.2022.54054","article-title":"Effectiveness of mycophenolate mofetil among patients with progressive IgA nephropathy: a randomized clinical trial","volume":"6","author":"Hou","year":"2023","journal-title":"JAMA Netw Open"},{"key":"2025042804361094200_bib38","doi-asserted-by":"publisher","first-page":"i123","DOI":"10.1093\/ndt\/gfw326","article-title":"Mycophenolate mofetil therapy in immunoglobulin A nephropathy: histological changes after treatment","volume":"32","author":"Beckwith","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"2025042804361094200_bib39","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.ekir.2023.10.015","article-title":"Mycophenolate mofetil and steroid for treatment of patients with IgA nephropathy","volume":"9","author":"Miao","year":"2024","journal-title":"Kidney Int Rep"},{"key":"2025042804361094200_bib40","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1093\/ckj\/sfab244","article-title":"Corticosteroids and mycophenolic acid analogues in immunoglobulin A nephropathy with progressive decline in kidney function","volume":"15","author":"Huerta","year":"2022","journal-title":"Clin Kidney J"},{"key":"2025042804361094200_bib41","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1016\/S0140-6736(17)30550-0","article-title":"Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial","volume":"389","author":"Fellstr\u00f6m","year":"2017","journal-title":"Lancet"},{"key":"2025042804361094200_bib42","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.kint.2022.09.017","article-title":"Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy","volume":"103","author":"Barratt","year":"2023","journal-title":"Kidney Int"},{"key":"2025042804361094200_bib43","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/S0140-6736(23)01554-4","article-title":"Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial","volume":"402","author":"Lafayette","year":"2023","journal-title":"Lancet"},{"key":"2025042804361094200_bib44","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1056\/NEJMoa2305635","article-title":"A phase 2 trial of sibeprenlimab in patients with IgA nephropathy","volume":"390","author":"Mathur","year":"2024","journal-title":"N Engl J Med"},{"key":"2025042804361094200_bib45","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1016\/j.kint.2024.03.012","article-title":"A phase 2b, randomized, double-blind, placebo-controlled, clinical trial of atacicept for treatment of IgA nephropathy","volume":"105","author":"Lafayette","year":"2024","journal-title":"Kidney Int"},{"key":"2025042804361094200_bib46","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1681\/ASN.2016060640","article-title":"A randomized, controlled trial of rituximab in IgA nephropathy with proteinuria and renal dysfunction","volume":"28","author":"Lafayette","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"2025042804361094200_bib47","doi-asserted-by":"publisher","first-page":"ii28","DOI":"10.1093\/ckj\/sfad198","article-title":"Targeting complement in IgA nephropathy","volume":"16","author":"Caravaca-Font\u00e1n","year":"2023","journal-title":"Clin Kidney J"},{"key":"2025042804361094200_bib48","doi-asserted-by":"publisher","first-page":"897","DOI":"10.2215\/CJN.09710913","article-title":"Association of C4d deposition with clinical outcomes in IgA nephropathy","volume":"9","author":"Espinosa","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025042804361094200_bib49","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1681\/ASN.2010111130","article-title":"A clinicopathologic study of thrombotic microangiopathy in IgA nephropathy","volume":"23","author":"El Karoui","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"2025042804361094200_bib50","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.kint.2023.09.027","article-title":"Results of a randomized double-blind placebo-controlled phase 2 study propose iptacopan as an alternative complement pathway inhibitor for IgA nephropathy","volume":"105","author":"Zhang","year":"2024","journal-title":"Kidney Int"},{"key":"2025042804361094200_bib51","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.0000000534","article-title":"Efficacy and safety of ravulizumab in IgA nephropathy. A phase 2 randomized double-blind placebo-controlled trial","author":"Lafayette","year":"2024","journal-title":"J Am Soc Nephrol"},{"key":"2025042804361094200_bib52","doi-asserted-by":"publisher","first-page":"452","DOI":"10.2215\/CJN.0000000000000384","article-title":"Phase 2 trial of cemdisiran in adult patients with IgA nephropathy: a randomized controlled trial","volume":"19","author":"Barratt","year":"2024","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025042804361094200_bib53","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2410316","article-title":"Alternative complement pathway inhibition with iptacopan in IgA nephropathy","volume":"392","author":"Perkovic","year":"2025","journal-title":"N Engl J Med"},{"key":"2025042804361094200_bib54","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1053\/j.ajkd.2019.01.026","article-title":"Effects of hydroxychloroquine on proteinuria in IgA nephropathy: a randomized controlled trial","volume":"74","author":"Liu","year":"2019","journal-title":"Am J Kidney Dis"},{"key":"2025042804361094200_bib55","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.kint.2021.03.033","article-title":"A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy","volume":"100","author":"Wheeler","year":"2021","journal-title":"Kidney Int"},{"key":"2025042804361094200_bib56","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.1681\/ASN.2014070697","article-title":"Corticosteroids in IgA nephropathy: a retrospective analysis from the VALIGA study","volume":"26","author":"Tesar","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"2025042804361094200_bib57","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1186\/1471-2369-15-193","article-title":"Efficacy and safety of mycophenolate mofetil treatment in IgA nephropathy: a systematic review","volume":"15","author":"Chen","year":"2014","journal-title":"BMC Nephrol"},{"key":"2025042804361094200_bib58","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1007\/s00467-016-3502-6","article-title":"IgA nephropathy with presentation of nephrotic syndrome at onset in children","volume":"32","author":"Shima","year":"2017","journal-title":"Pediatr Nephrol"},{"key":"2025042804361094200_bib59","doi-asserted-by":"publisher","first-page":"16001","DOI":"10.1038\/nrdp.2016.1","article-title":"IgA nephropathy","volume":"2","author":"Lai","year":"2016","journal-title":"Nat Rev Dis Prim"},{"key":"2025042804361094200_bib60","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/ki.1985.120","article-title":"Acute worsening of renal function during episodes of macroscopic hematuria in IgA nephropathy","volume":"28","author":"Praga","year":"1985","journal-title":"Kidney Int"},{"key":"2025042804361094200_bib61","doi-asserted-by":"crossref","first-page":"51","DOI":"10.2215\/CJN.02670706","article-title":"Factors that determine an incomplete recovery of renal function in macrohematuria-induced acute renal failure of IgA nephropathy","volume":"2","author":"Guti\u00e9rrez","year":"2007","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025042804361094200_bib62","doi-asserted-by":"publisher","first-page":"175","DOI":"10.2215\/CJN.01970211","article-title":"AKI associated with macroscopic glomerular hematuria: clinical and pathophysiologic consequences","volume":"7","author":"Moreno","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025042804361094200_bib63","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.2215\/CJN.13251118","article-title":"IgA nephropathy in elderly patients","volume":"14","author":"Sevillano","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025042804361094200_bib64","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/j.ekir.2022.01.1048","article-title":"IgA nephropathy is the most common underlying disease in patients with anticoagulant-related nephropathy","volume":"7","author":"Trujillo","year":"2022","journal-title":"Kidney Int Rep"},{"key":"2025042804361094200_bib65","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1016\/j.ekir.2023.05.027","article-title":"Effect of immunosuppressive treatments on kidney outcomes after gross hematuria-related acute kidney injury in older patients with IgA nephropathy","volume":"8","author":"Sevillano","year":"2023","journal-title":"Kidney Int Rep"},{"key":"2025042804361094200_bib66","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1093\/ndt\/gfg081","article-title":"Crescentic, proliferative IgA nephropathy: clinical and histological response to methylprednisolone and intravenous cyclophosphamide","volume":"18","author":"Tumlin","year":"2003","journal-title":"Nephrol Dial Transplant"},{"key":"2025042804361094200_bib67","doi-asserted-by":"publisher","first-page":"2118","DOI":"10.1681\/ASN.2012101017","article-title":"Prediction of outcomes in crescentic IgA nephropathy in a multicenter cohort study","volume":"24","author":"Lv","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"2025042804361094200_bib68","first-page":"42","article-title":"Malignant hypertension: a type of IgA nephropathy manifestation with poor prognosis","volume":"35","author":"Sevillano","year":"2015","journal-title":"Nefrologia"},{"key":"2025042804361094200_bib69","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1093\/ndt\/gfac248","article-title":"Thrombotic microangiopathy in patients with malignant hypertension","volume":"38","author":"Cavero","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"2025042804361094200_bib70","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1053\/j.ajkd.2019.03.416","article-title":"Microangiopathic lesions in IgA nephropathy: a cohort study","volume":"74","author":"Cai","year":"2019","journal-title":"Am J Kidney Dis"},{"key":"2025042804361094200_bib71","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1093\/ndt\/gfz241","article-title":"Glomerular endothelial activation, C4d deposits and microangiopathy in immunoglobulin A nephropathy","volume":"36","author":"Trimarchi","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"2025042804361094200_bib72","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1016\/j.ekir.2022.03.028","article-title":"The role of complement in microangiopathic lesions of IgA nephropathy","volume":"7","author":"Li","year":"2022","journal-title":"Kidney Int Rep"},{"key":"2025042804361094200_bib73","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1159\/000485194","article-title":"Atypical hemolytic uremic syndrome associated with complement factor H mutation and IgA nephropathy: a case report successfully treated with eculizumab","volume":"138","author":"Nakamura","year":"2018","journal-title":"Nephron"},{"key":"2025042804361094200_bib74","doi-asserted-by":"publisher","first-page":"212","DOI":"10.3390\/jcm7080212","article-title":"A systematic review on materno-foetal outcomes in pregnant women with IgA nephropathy: a case of \u201clate-maternal\u201d preeclampsia?","volume":"7","author":"Piccoli","year":"2018","journal-title":"J Clin Med"},{"key":"2025042804361094200_bib75","doi-asserted-by":"publisher","first-page":"447","DOI":"10.5414\/CN107208","article-title":"Reduced pre-pregnancy proteinuria is associated with improving postnatal maternal renal outcomes in IgA nephropathy women","volume":"76","author":"Oh","year":"2011","journal-title":"Clin Nephrol"},{"key":"2025042804361094200_bib76","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.kint.2022.10.029","article-title":"Glomerular diseases in pregnancy: pragmatic recommendations for clinical management","volume":"103","author":"Fakhouri","year":"2023","journal-title":"Kidney Int"},{"key":"2025042804361094200_bib77","doi-asserted-by":"publisher","first-page":"sfae084","DOI":"10.1093\/ckj\/sfae084","article-title":"Pre-gestational counselling for women living with CKD: starting from the bright side","volume":"17","author":"Da Silva","year":"2024","journal-title":"Clin Kidney J"},{"key":"2025042804361094200_bib78","doi-asserted-by":"publisher","first-page":"127083","DOI":"10.1155\/2015\/127083","article-title":"Is it possible to differentiate chronic kidney disease and preeclampsia by means of new and old biomarkers? A prospective study","volume":"2015","author":"Rolfo","year":"2015","journal-title":"Dis Markers"},{"key":"2025042804361094200_bib79","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1093\/ndt\/5.8.619","article-title":"Mesangial IgA disease with crescent formation during pregnancy: postpartum treatment with immunosuppression","volume":"5","author":"Isaacs","year":"1990","journal-title":"Nephrol Dial Transplant"},{"key":"2025042804361094200_bib80","doi-asserted-by":"publisher","first-page":"e0610","DOI":"10.1097\/MD.0000000000010610","article-title":"Tacrolimus decreases proteinuria in patients with refractory IgA nephropathy","volume":"97","author":"Hu","year":"2018","journal-title":"Medicine (Baltimore)"},{"key":"2025042804361094200_bib81","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.2215\/CJN.00910121","article-title":"Recurrence of IgA nephropathy after kidney transplantation in adults","volume":"16","author":"Uffing","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025042804361094200_bib82","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.kint.2016.08.030","article-title":"Recent advances in our understanding of recurrent primary glomerulonephritis after kidney transplantation","volume":"91","author":"Cosio","year":"2017","journal-title":"Kidney Int"},{"key":"2025042804361094200_bib83","doi-asserted-by":"publisher","first-page":"2855","DOI":"10.1111\/ajt.15400","article-title":"Clinical importance of the updated Oxford classification in allograft IgA nephropathy","volume":"19","author":"Park","year":"2019","journal-title":"Am J Transplant"},{"key":"2025042804361094200_bib84","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1016\/j.ajt.2023.05.031","article-title":"Eculizumab as a therapeutic approach for severe crescentic recurrence of immunoglobulin A nephropathy after kidney transplantation","volume":"23","author":"Duval","year":"2023","journal-title":"Am J Transplant"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ndt\/advance-article-pdf\/doi\/10.1093\/ndt\/gfae289\/61218715\/gfae289.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/40\/5\/874\/61218715\/gfae289.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/40\/5\/874\/61218715\/gfae289.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T04:36:21Z","timestamp":1745814981000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/40\/5\/874\/7926970"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,17]]},"references-count":84,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,12,17]]},"published-print":{"date-parts":[[2025,4,28]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfae289","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,5]]},"published":{"date-parts":[[2024,12,17]]}}}